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Background: Lichen-derived glucans have been known to 
stimulate the functions of immune cells. However, im-
munostimulatory activity of glucan obtained from edible li-
chen, Umbilicaria esculenta, has not been reported. Thus we 
evaluated the phenotype and functional maturation of den-
dritic cells (DCs) following treatment of extracted glucan 
(PUE). Methods: The phenotypic and functional maturation 
of PUE-treated DCs was assessed by flow cytometric analy-
sis and cytokine production, respectively. PUE-treated DCs 
was also used for mixed leukocyte reaction to evaluate T 
cell-priming capacity. Finally we detected the activation of 
MAPK and NF-κB by immunoblot. Results: Phenotypic ma-
turation of DCs was shown by the elevated expressions of 
CD40, CD80, CD86, and MHC class I/II molecules. Functio-
nal activation of DCs was proved by increased cytokine pro-
duction of IL-12, IL-1β, TNF-α, and IFN-α/β, decreased 
endocytosis, and enhanced proliferation of allogenic T cells. 
Polymyxin B, specific inhibitor of lipopolysaccharide (LPS), 
did not affect PUE activity, which suggested that PUE was 
free of LPS contamination. As a mechanism of action, PUE 
increased phosphorylation of ERK, JNK, and p38 MAPKs, 
and enhanced nuclear translocation of NF-κB p50/p65 in 
DCs. Conclusion: These results indicate that PUE induced 
DC maturation via MAPK and NF-κB signaling pathways.
[Immune Network 2010;10(6):188-197]
INTRODUCTION
In recent decades, glucan polysaccharides isolated from bota-
nical  sources,  including  plants,  mushrooms,  algae,  and  li-
chens,  have  attracted  a  great  deal  of  attention  in  the  bio-
medical area because of their broad spectrum of therapeutic 
properties and relatively low toxicities (1-3). While the mech-
anism of action is still unclear, it appears that one of the pri-
mary mechanisms involves nonspecific activation of the im-
m u n e  s y s t e m  ( 2 ) .  I n d e e d ,  t h e  b a s i c  m e c h a n i s m  o f  t h e  i m-
munostimulatory,  anti-tumor,  anti-infection,  and  other  ther-
apeutic effects of glucans is thought to occur via the modu-
lation of innate immunity including macrophage and dendritic 
cell  (DC)  functions  (1).
  T h e  m a j o r i t y  o f  g l u c a n s  w e r e  i s o l a t e d  f r o m  m u s h r o o m s ,  
such as lentinan from lentinus eodes (4), schzophyllan from 
Schizophyllum commune (5), krestin from Coriolus versicolor 
(6), grifolan from Grifola frondosa (7), and scleroglucan from 
Sclerotinia sclerotiorum (8). Similarly, glucans were isolated 
from lichens, including lichenan and isolichenan from Cetraria 
islandica (9-11) and thamnolan from Thamnolia subuliformis 
(11-13). Lichen-derived glucans stimulated immune functions 
of DCs, macrophages, and spleen cells (10,12). In this study, 
we investigated immunomodulating activity of glucan isolated 
from an edible lichen Umbilicaria esculenta, which had been 
used for a traditional food or a medicine in the Far East such 
as Korea, Japan and China (14). Extracts or prescriptions of Dendritic Cell Activation by Umbilicaria Esculenta
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Umbilicaria esculenta showed inhibitory activities on throm-
bosis (14), melanogenesis (15), and glycosidase (16). However, 
immunomodulatory activity of glucan from U. esculenta has 
not been reported yet. We investigated here the immunostim-
ulatory  activity  of  glucan  isolated  from  U.  esculenta,  espe-
cially  focusing  on  DC  functions.
MATERIALS AND METHODS
Materials
Female  C57BL/6  and  BALB/c  mice  (6∼8  weeks  old)  were 
obtained  from  Korea  Research  Institute  of  Bioscience  and 
Biotechnology (Chungbuk, Korea). Mice were housed in spe-
cific pathogen-free conditions at 21∼24
oC and 40∼60% rela-
tive humidity under a 12-h light/dark cycle. All animals were 
acclimatized for at least 1 week prior to the experiments. The 
e x p e r i m e n t a l  p r o c e d u r e s  u s e d  i n  t h i s  s t u d y  w e r e  a p p r o v e d 
by the Animal Experimentation Ethics Committee in Chungbuk 
National University. Antibodies against mouse CD11c, CD40, 
CD80, CD86, and MHC class  I/II were purchased from BD 
Pharmingen  (San Diego,  CA, USA),  and  those against ERK, 
p38, JNK, p65, and p50 were purchased from Cell Signaling 
Technology  (Beverly,  MA,  USA). 
Isolation of crude glucan (PUE) from Umbilicaria 
esculenta
PUE  was  extracted  from  an  edible  lichen  U.  esculenta. 
Briefly, the dried U. esculenta was pulverized into powder. 
The sample was then defatted three times with dichloromethane. 
After  centrifugation,  the  residue  was  successively  extracted 
twice with hot water (100
oC) each time for 2 h. The extract 
was combined and concentrated under reduced pressure to 
small volumes. The crude polysaccharide was precipitated by 
adding two volumes of ethanol. The precipitate was collected 
by centrifugation and washed twice with ethanol. The precip-
itate was then suspended in water and lyophilized to yield 
crude  glucan,  named  as  PUE.  PUE  included  70.8%  of  im-
munostimulating  glucan  (Megazyme,  Wicklow,  Ireland).  No 
endotoxin was detected at concentrations up to 500 μg/ml 
PUE, which was determined by LAL test (Catalogue number 
291-53101,  Wako  Pure  Chemicals,  Osaka,  Japan).
Nitrite production assay
RAW264.7 macrophages were plated at 5×10
5 cells/ml and 
then  stimulated  with  PUE  or  LPS  for  24  h.  Isolated  super-
natants were mixed with an equal volume of Griess reagent 
and then incubated at room temperature for 10 min. Nitrite 
production was determined by measuring absorbance at 540 
nm  versus  a  NaNO2-derived  standard  curve  (17).
Lymphoproliferation assay
Spleen  cells  were  obtained  from  a  specific  pathogen-free 
C57BL/6 mouse (female, 6∼7 weeks old) and freed of red 
blood cells by treating with lysis buffer. Spleen cells were cul-
tured in RPMI 1640 medium supplemented with 10% fetal calf 
serum (Invitrogen, Carlsbad, CA, USA), 2 mM glutamine and 
50 μM 2-mercaptoethanol (Sigma, St. Louis, MO, USA). Cells 
were seeded in a 96-well, flat-bottomed plate at a density of 
2×10
5  cells/well  and  stimulated  with  PUE  or  lipopolysa-
ccharide  (LPS)  (17).  Cells  were  pulsed  with 
3H-thymidine 
(113 Ci/nmol, NEN, Boston, MA, USA) at a concentration of 
1μCi/well  for  the  last  18  h  and  harvested  on  day  3  using 
an automated cell harvester (Inotech, Dottikon, Switzerland). 
The amount of 
3H-thymidine incorporated into the cells was 
measured  using  a  Wallac  Microbeta  scintillation  counter 
(Wallac,  Turku,  Finland).
Generation of bone marrow-derived dendritic cells 
(DCs)
DCs were generated from bone marrow (BM) cells obtained 
from 6∼7-week-old female mice (18). Briefly, BM cells were 
flushed out from femurs and tibias. After red blood cells were 
lysed, whole BM cells (2×10
5 cells/ml) were cultured in 100- 
mm
2 culture dishes in 10 ml/dish of complete medium con-
taining  2  ng/ml  GM-CSF  (R&D  Systems,  Minneapolis,  MN, 
USA). On day 3, another 10 ml of fresh complete medium 
containing 2 ng/ml GM-CSF was added, and half of the me-
dium was changed on day 6. On day 8, non-adherent and 
loosely adherent DCs were harvested by vigorous pipetting 
and used as immature DCs (iDCs). iDCs recovered from these 
cultures were generally ＞85% CD11c
＋, but not CD3
＋ and 
B220
＋.
Phenotype analysis
Phenotypic maturation of DCs was analyzed by flow cytometry 
(19). Cell were stained using a combination of FITC-conjugated 
anti-CD40,  anti-CD80,  anti-CD86 ,  o r  a n t i - M H C  p l u s  P E - c o n -
jugated  CD11c  antibodies.  Cells  were  analyzed  using  a 
FACSCanto  flow  cytometer  (BD  Biosciences,  San  Jose,  CA, 
USA),  and  data  were  analyzed  using  WinMdi  software 
(Scripps, La Jolla, CA, USA). Forward and side scatter param-
eters were used to gate live cells. Cell viability was examined Dendritic Cell Activation by Umbilicaria Esculenta
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by the propidium iodide (PI) nuclear staining method. Cells 
w e r e  s t a i n e d  w i t h  1  μg/ml  of  PI  and  analyzed  with  a 
FACSCanto flow cytometer. Cells stained with PI were consid-
ered  dead  cells. 
Endocytosis assay
T o  a n a l y z e  t h e  e n d o c y t o s i s  o f  D C s ,  4 × 1 0
5 D C s  w e r e  i n -
cubated at 37
oC for 1 h with 0.7 mg/ml FITC-dextran (42,000 
Da,  Sigma-Aldrich,  St.  Louis,  MO,  USA).  After  incubation, 
cells were washed twice with cold washing buffer (PBS con-
taining  0.5%  BSA)  and  stained  using  PE-conjugated  an-
ti-CD11c  antibody.  Double-stained  DCs  were  analyzed  by 
flow cytometry. Parallel experiments were performed at 4
oC 
to determine the nonspecific binding of FITC-dextran to DCs 
(20).
Cytokine assay
Total RNA was isolated using TRIZOL
TM Reagent (Molecular 
Research  Center,  Cincinnati,  OH,  USA).  For  RT-PCR,  sin-
gle-strand cDNA was synthesized from 2 μg total RNA. The 
primer  sequences  used  were  as  follows  (20):  IL-12,  sense, 
5’-AGA GGT GGA CTG GAC TCC CGA-3’, antisense, 5’-TTT 
GGT GCT TCA CAC TTC AG-3’; TNF-α, sense, 5’-AGG TTC 
TGT CCC TTT CAC TCA CTG-3’, antisense, 5’-AGA GAA CCT 
GGG AGT CAA GGT A-3’; IL-1β, sense, 5’-ATG GCA ATG 
TTC  CTG  AAC  TCA  ACT-3’,  antisense,  5’-CAG  GAC  AGG 
TAT AGA TTC TTT CCT TT-3’; IFN-α, sense, 5’-TCT GAT 
GCA GCA GGT GGG-3’, antisense, 5’-AGG GCT CTC CAG 
AYT TCT GCT CTG-3’; IFN-β, sense, 5’-CCA CAG CCC TCT 
CCA TCA ACT ATA AGC-3’, antisense, 5’-AGC TCT TCA ACT 
GGA GAG CAG TTG AGG-3’; β-actin, sense, 5’-TGG AAT 
CCT  GTG  GCA  TCC  ATG  AAA  C-3’,  and  antisense  5’-TAA 
AAC GCA GCT CAG TAACAG TCC G-3’. PCR products were 
fractionated on 1% agarose gels and stained with 5  μg/ml 
ethidium bromide. After analyzing band areas using an ImageJ 
analysis  system  (ImageJ,  NIH,  MD,  USA),  target  mRNA  ex-
pression  levels were calculated as  relative ratios  versus  β- 
actin.  Cytokine  levels  of  IL-2  and  IFN-γ i n  c u l t u r e  s u p e r -
natants were measured using commercial immunoassay kits 
(R&D  Systems,  Minneapolis,  MN,  USA).
Western blots
Cell lysates were prepared as previously described (18). De-
tergent-insoluble materials were removed, and equal amounts 
of  protein  were  fractionated  by  10%  SDS-PAGE  and  trans-
ferred  to  pure  nitrocellulose  membranes.  Membranes  were 
b lo c k e d w it h 5 % BS A in  Tw ee n  2 0  p lu s TB S (TT BS ) f or  1 
h and then incubated with an appropriate dilution of primary 
antibody in 5% BSA (in TTBS) for 2 h. Blots were incubated 
with biotinylated antibody for 1 h and further incubated with 
HRP-conjugated  streptavidin  for  1  h.  Signals  were  detected 
by  enhanced  chemiluminescence  (Amersham  Pharmacia 
Biotech,  Piscataway,  NJ,  USA).
Mixed leukocyte reaction (MLR)
Responder T cells were purified from the spleen of BALB/c 
mice  by  negative  depletion  using  biotinylated  antibodies 
against B220, GR-1, and CD11c (BD Pharmingen, San Diego, 
CA,  USA)  and  Dynabeads  M-280  streptavidin  (Invitrogen, 
Carlsbad, CA, USA), as previously described (18). Purity was 
typically  more  than  90%.  DCs  generated  from  BM  cells  of 
C57BL/6  mice  were  treated  with  40  μg/ml  mitomycin  C 
(MMC)  for 1  h.  MMC-treated  DCs from  300  to  10,000  cells 
were  added  to  1×10
5 T  c e l l s  i n  U - b o t t o m  96-well  plates 
(activator: responder cell ratio=0.3-10). Allogenic T cells were 
pulsed with [
3H]-thymidine (113 Ci/nmol, NEN, Boston, MA, 
USA) at a concentration of 1 μCi/well for the last 18 h and 
then harvested on days 3 and 5 using an automated cell har-
vester (Innotech, Dottikon, Switzerland). The amount of [
3H]- 
thymidine incorporated into the cells was measured using a 
Wallac Microbeta scintillation counter (Wallac, Turku, Finland).
Statistical analysis
Data represent the mean±STD of more than three samples 
and all experiments were performed more than three times. 
Standard deviations (STD) and p values were calculated by 
ANOVA  (GraphPad  Software,  San  Diego,  CA,  USA).
RESULTS
Cell-type selectivity of PUE
First, we investigated the immunostimulating activities of PUE 
on  several  immune  cells  including  DCs,  macrophages,  and 
s p l e e n  c e l l s  ( m a i n l y  i n c l u d i n g  B  a n d  T  c e l l s )  t o  d e t e r m i n e  
cell-type selectivity. PUE increased NO production by RAW264.7 
macrophages  (Fig.  1A),  spleen  cell  proliferation  (Fig.  1B), 
and MHC class I expression in BM-derived DCs (Fig. 1C). LPS 
was used as a positive activator of B cells, macrophages, and 
dendritic  cells.  This  result  suggests  that  PUE  increases  im-
mune  functions  of  macrophages,  splenic  lymphocytes,  and 
DCs. Subsequently, we investigated the stimulating effect of 
PUE  on  maturation  and  function  of  DCs  in  greater  detail, Dendritic Cell Activation by Umbilicaria Esculenta
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since they were considered as main regulatory cells connect-
ing  innate  and  adoptive  immunity.
PUE induces the phenotypic maturation of DCs
We examined the phenotypic maturation of DCs by determin-
ing the expression level of MHC class II, CD40, and CD80/86, 
which were involved in T cell activation. PUE increased the 
expression of MHC class II (Fig. 2A), CD40 (Fig. 2B), CD80 
( F i g .  2 C ) ,  a n d  C D 8 6  i n  d o s e - d e p e n d e n t  m a n n e r  ( F i g .  2 D ) .  
PUE- or LPS-treated DCs showed a mature morphology with 
long dendrites, but untreated DCs had short dendrites. Mature 
DCs were increased in size and granularity, as indicated by 
the forward- and side-scatter values on flow cytometry. PUE 
or LPS did not affect cell viability during the incubation (data 
not shown). These results demonstrate that PUE induces the 
phenotypic  maturation  of  DCs. 
    The field of glucan research has been confounded by the 
presence of the endotoxin LPS in glucan preparations. To rule 
out the possibility of LPS contamination in PUE, we treated 
P U E  w i t h  p o l y m y x i n  B  ( P M B ) ,  a  s p e c i f i c  i n h i b i t o r  o f  L P S .  
PMB strongly inhibited MHC class II expression by LPS-treat-
e d  D C s ,  b u t  n o t  b y  P U E - t r e a t e d  D C s  ( F i g .  2 E ) .  T h i s  r e s u l t  
suggests that the PUE was free of LPS contamination and that 
the  DC  maturation  was  glucan  specific.
PUE induces functional maturation of DCs
Cytokine expression is a parameter of functional maturation 
of  DCs.  PUE  strongly  increased  IL-12  gene  expression  by 
DCs, which is a major factor in the induction of Th1 immune 
r e s p o n s e  ( F i g .  3 A ) .  I n  a d d i t i o n ,  P U E  i n c r e a s e d  g e n e  e x -
pression of pro-inflammatory cytokines, such as IL-1β, TNF-α, 
and IFN-α/β by DCs. Immature DCs efficiently capture anti-
Figure 1. Cell-type selectivity of PUE. RAW 264.7 macrophages 
were treated with PUE for 24 h and NO production was determined 
(A). Spleen cells were treated with PUE for 72 h and 
lymphoproliferation was determined (B). Immature DCs were 
treated with PUE for 24 h and MHC class I expression level was 
determined (C). LPS (1 μg/ml) was used as a general activator of 
DCs, RAW 264.7 cells, and B cells. Significance was determined 
using the ANOVA test versus chemically-untreated control groups 
(UN) (*p＜0.01).Dendritic Cell Activation by Umbilicaria Esculenta
Hyung Sook Kim, et al.
192 IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 6 December 2010
gens and show a high level of endocytosis, but mature DCs 
h a v e  r e d u c e d  a n t i g e n  c a p t u r e  c a p a c i t i e s .  P U E - t r e a t e d  D C s  
showed reduction of antigen-uptake in dose-dependent man-
ner (Fig. 3B). A similar result was obtained with LPS-treated 
DCs. Parallel experiments were performed at low temperature 
to  rule  out  nonspecific  binding  of  dextran-FITC  to  DCs. 
Antigen  uptake  by  DCs  was  inhibited  at  low  temperature, 
which suggested that DC endocytosis was a specific, active 
Figure 2. Phenotypic maturation of DCs by PUE. Immature DCs were 
treated with LPS (1 μg/ml) or PUE. After incubation for 24 h, DCs 
were stained with PE-conjugated CD11c Ab plus FITC-conjugated Abs 
against MHC class II (A), CD40 (B), CD80 (C), and CD86 (D). 
CD11c-PE was used to gate live DCs. Results are presented as 
mean±STD. In another experiment, PUE or LPS was pre-treated with 
1,000 units/ml PMB for 2 h or left untreated, and then incubated with 
immature DCs. After incubation for 24 h, cells were stained with 
PE-conjugated CD11c Ab plus FITC-conjugated MHC class II Ab (E). 
Mean fluorescence intensities (MFI) of three separate experiments are 
shown. Significances were determined using the ANOVA test versus 
chemically-untreated control groups (UN) (*p＜0.01) and versus 
PMB-untreated group (
†p＜0.01).Dendritic Cell Activation by Umbilicaria Esculenta
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Figure 3. Effect of PUE on cytokine gene expression of DCs. (A) 
Immature DCs were activated with LPS or PUE for 4 h. Then, total 
RNA was isolated and RT-PCR was performed to examine gene 
expression levels of IL-12, IL-1β, TNF-α, and IFN-α/β. (B) 
Immature DCs were activated with LPS or PUE for 24 h and then 
treated with 0.7 mg/ml of dextran-FITC for 1 h at 37
oC. After 
washing, DCs were stained with PE-conjugated anti-CD11c Ab and 
double-stained DCs were analyzed by flow cytometry. Parallel 
experiments were performed at 4
oC to confirm nonspecific binding 
of FITC-dextran. Mean fluorescence intensities (MFI) of three 
separate experiments are shown. Significances were determined 
using the ANOVA test versus chemically-untreated control groups 
(UN) (*p＜0.01).
Figure 4. Allo-stimulation of T cells using PUE-treated DCs. Immature DCs were activated with LPS or PUE for 24 h, and treated with 40 μg/ml
mitomycin C (MMC) for 1 h to prevent proliferation. MMC-treated DCs (300~10,000) were added to 1×10
5 T cells per well. After incubation
for 3 (A) and 5 days (B), mixed cell populations were labeled with [
3H]-thymidine and harvested using an automated cell harvester.Dendritic Cell Activation by Umbilicaria Esculenta
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Figure 5. Effect of PUE on MAPK signalings. iDCs were generated from
mouse BM cells by treating them with 2 ng/ml of GM-CSF for 8 days,
and then further activated with LPS (1 μg/ml) or PUE for 15 min.
Total cell extracts were isolated and blotted with anti-phospho-ERK,
-JNK, and -p38 antibodies. UN, chemically-untreated control groups.
Figure 6. Effect of PUE on NF-κB signalings. iDCs were generated 
from mouse BM cells by treating them with 2 ng/ml of GM-CSF for 
8 days, and then further activated with LPS (1 μg/ml) or PUE for 6 
h and nuclear extracts were blotted with anti-p50 and anti-p65 
antibodies. UN, chemically-untreated control groups.
process. These results demonstrate that PUE induces the func-
tional  maturation  of  DCs.
PUE-treated DCs show enhanced allogenic T cell pro-
liferation
The  phenotypic and  functional  maturations  of  DCs  by  PUE 
suggest that PUE-treated DCs might play a role as stimulator 
cells during allogenic T cell responses. To test this hypoth-
esis,  we  induced  mixed  leukocyte  response  using  C57BL/6 
mouse-derived DCs (H-2
b) and BALB/c mouse-derived T cells 
(H-2
d). After three (Fig. 4A) or five days (Fig. 4B), PUE-treat-
ed DCs strongly enhanced allogenic T cell proliferation, but 
i m m a t u r e  D C s  s l i g h t l y  a f f e c t e d  t h i s  r e s p o n s e .  T  c e l l s  o r  
MMC-treated DCs alone could not proliferate. These results 
suggest that PUE-treated DCs have high capacity to stimulate 
allogenic  T  cells  to  proliferate  and  produce  cytokines.
PUE induces phosphorylation of MAPKs and nuclear 
translocation of NF-κB p50/65
Signaling pathways involving NF-κB and MAPK play a major 
role in DC maturation. Thus, we investigated the activation 
of MAPKs and NF-κB in PUE-treated DCs. As shown in Fig. 
5, basal levels of phosphorylated ERK, JNK, and p38 MAPKs 
i n  i m m a t u r e  D C s  w e r e  l o w ,  w h e r e a s  p h o s p h o r y l a t i o n  o f  
MAPKs were profoundly increased over basal levels in DCs 
upon exposure to either LPS or PUE, indicating that MAPK 
pathways might be involved in PUE-induced DC maturation. 
The majority of NF-κB subunits are sequestered in the cyto-
plasm by IκBα/β and translocated into the nucleus after 
IκBα/β degradation. As shown in Fig. 6, PUE induced the 
nuclear  translocation  of  NF-κB  p50  and  p65,  as  demon-
strated by the increased levels of nuclear p50/p65 proteins. 
These  results  suggested  that  PUE  induced  DC  maturation 
through  MAPK  and  NF-κB  signalings.
DISCUSSION
U.  esculenta  is  an  edible  and  medicinal  lichen  containing 
large amounts of β-1,3-glucan (PUE) and we show here that Dendritic Cell Activation by Umbilicaria Esculenta
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PUE has immunostimulating activities. In general, antitumor 
immunity in physiological conditions is coordinated by both 
innate and adaptive immunity, and is mainly mediated by di-
verse  immune  effector  cells,  such  as  DCs,  macrophages,  T 
cells, B cells, and others. In this study, we examined the di-
r e c t  e f f e c t  o f  P U E  o n  i m m u n e  e f f e c t o r  c e l l s  a n d  w e  f o u n d 
that  PUE  activated  DCs  and  macrophages,  and  spleen  cells 
(mainly consisting of B and T cells). In the subsequent stud-
ies, we tried to investigate the effect of PUE on DCs in greater 
detail, since they are main regulating players, which can in-
duce, coordinate, and regulate antitumor immunity (21). DCs 
are  professional  antigen-presenting  cells  that  are  crucial  for 
the initiation of tumor-specific T cell responses (21). DCs are 
scattered through the body as immature cells with potent anti-
gen-uptake  functions.  On  receiving  cytokines  or  other  in-
flammatory mediators, they mature and migrate to the T cell 
zones of draining lymph nodes, and sensitize T cells through 
major histocompatibility (MHC) and co-stimulatory molecules 
(22). This fact suggests that a maturation step is essential for 
DCs to initiate T cell activation. Especially, DC maturation is 
a critical step in inducing anti-tumor immunity. Solid tumors 
contain small number of DCs, and most of them are immature 
cells (23). These immature DCs cannot induce antitumor im-
mune responses (24). In addition, it has been reported that 
tumors prevent DC maturation and functions by releasing im-
munosuppressive  factors,  such  as  VEGF,  PGE2,  and  IL-10 
(25-30). During the past several decades, many studies have 
attempted to find immunomodulators that induce DC matu-
ration. In particular, plant-derived polysaccharides have been 
suggested as promising candidates for DC maturation. For ex-
ample, glucan polysaccharides isolated from Phellinus linteus, 
Agaricus blazei, Coriolus versicolor, Cordyceps militaris, and 
Angelica  gigas  have  been  found  to  induce  phenotypic  and 
functional  maturation  of  murine  immature  DCs  (19,  31-34). 
Here, we demonstrate that PUE from U. esculenta might also 
be  a  good  inducer  of  DC  maturation.
    Several phenotypic and functional changes were observed 
in PUE-treated DCs. PUE increased expressions of MHC class 
I/II and of co-stimulatory molecules (CD40 and CD80/86), re-
sulting in enhanced antigen presentation to T cells (35). PUE 
also increased cytokine production by DCs. Among DC-de-
rived cytokines, IL-12 is the main cytokine that can activate 
Th1 cells. Activated Th1 cells can produce IFN-γ and IL-2, 
which can activate antitumor effector cells, such as cytotoxic 
T cells and NK cells (36). In addition, other inflammatory cy-
tokines (TNF-α and IL-1β) produced by DCs can up-regu-
late adhesion molecules by the endothelium and these mole-
cules contribute to the recruitment of monocytes and other 
cell types to the tumor microenvironment (37). These results 
suggest  that  PUE  activated  DCs  and  resulted  in  the  overall 
activation of antitumor effector cells in tumor environments. 
PUE-induced DC maturation is likely to involve at least two 
important signaling pathways: MAPKs and NF-κB/Rel. This 
coordinated process in DCs leads to IL-12 release and to a 
high T cell-stimulatory capacity, both of which result in the 
induction of a protective immune response. Our results show 
that PUE induces DC maturation through MAPK and NF-κB 
activation.
    One question raised in this study might be whether PUE 
was free of LPS contamination. The field of glucan research 
has been confounded by the presence of the endotoxin LPS 
in glucan preparations. In this study, to rule out the possi-
bility of LPS contamination in PUE, we validated PUE purity 
in two different ways. First, we treated PUE with polymyxin 
B (PMB), a specific inhibitor of LPS. PMB strongly inhibited 
MHC  class  II  expression  by  LPS-treated  DCs,  but  not  by 
PUE-treated DCs. Second, we examined endotoxin levels in 
PUE  by  using  Limulus  Amebocyte  Lysate  (LAL)  test  and 
proved that no endotoxin was detected at concentrations up 
to 500 μg/ml PUE. This result suggested that the PUE was 
free  of  LPS  contamination  and  that  DC  maturation  was  β- 
glucan  specific. 
    The body’s natural defenses are usually attenuated in can-
cer patients. In particular, DCs that are infiltrated into tumor 
tissues show reduced expression of co-stimulatory molecules 
and  defective  cytokine  production,  which  implies  that  tu-
mor-derived factors impede DC maturation (22,23). Defective 
D C s  i n  t u m o r  m i c r o e n v i r o n m e n t s  i s  a n  i m p o r t a n t  i m m u n o -
logical problem that limits the success of cancer immunotherapy. 
In the present study, we find that PUE can induce the pheno-
typic  and  functional  maturation  of  DCs  through  MAPK  and 
NF-κB signaling, which suggests that PUE might increase the 
efficiency  of  DC-based  cancer  immunotherapy.
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